Pulmonary Medicine Reference
Comprehensive Guide to Oxygen Therapy | Clinical Review

Comprehensive Guide to Oxygen Therapy A Clinical Review for Medical Professionals — Updated

1. Introduction and Core Physiology

The Purpose of Oxygen Therapy

Oxygen is an active pharmacological agent—a drug—that must be prescribed with specific targets. The primary goal of oxygen therapy is to treat or prevent hypoxia (inadequate tissue oxygenation), reducing the workload on the heart and lungs.

Hypoxemia vs. Hypoxia

  • Hypoxemia: Refers to an abnormally low concentration of oxygen in the arterial blood (low PaO₂ or low SpO₂). It is a measurable laboratory/clinical value.
  • Hypoxia: Refers to a state where there is a deficiency of oxygen reaching the tissues. While hypoxemia often leads to hypoxia, a patient can be hypoxic without being hypoxemic (e.g., severe anemia or carbon monoxide poisoning, where blood oxygen content is low despite a normal PaO₂).

Mechanisms of Hypoxemia (The "Why")

Understanding the mechanism is crucial for choosing the right therapy:

  • V/Q Mismatch (Ventilation/Perfusion Mismatch): The most common cause. Certain areas of the lung are perfused but poorly ventilated (e.g., asthma, COPD). Generally responsive to supplemental oxygen.
  • Right-to-Left Shunt: Alveoli are completely unventilated but still perfused (e.g., ARDS, severe pneumonia with dense consolidation). Highly resistant to supplemental oxygen; requires positive pressure (PEEP) to recruit alveoli.
  • Hypoventilation: Inadequate movement of air in and out of the lungs (e.g., opiate overdose, neuromuscular disease). Results in hypercapnia (high CO₂) alongside hypoxemia. This is the only mechanism of hypoxemia that results in a normal Alveolar-arterial (A-a) gradient.
  • Diffusion Impairment: Thickened alveolar-capillary membrane impedes gas exchange (e.g., Interstitial Lung Disease). Worsens significantly with exertion.

2. Clinical Assessment and Monitoring

Recognizing Respiratory Distress

  • Work of Breathing: Tachypnea (>25 breaths/min), use of accessory muscles (sternocleidomastoid, scalenes), abdominal paradox.
  • Systemic Signs: Central cyanosis (blue lips/tongue indicates >5g/dL of deoxygenated hemoglobin), altered mental status (confusion, agitation, lethargy), tachycardia, diaphoresis.

Pulse Oximetry (SpO₂)

Provides a non-invasive, continuous estimate of arterial hemoglobin saturation.

  • Poor Perfusion: Cold extremities, hypotension, or cardiac arrest can cause artificially low or unreadable signals.
  • Carbon Monoxide Poisoning: Standard oximeters cannot distinguish between carboxyhemoglobin and oxyhemoglobin; SpO₂ will falsely read as normal (e.g., 99%) even if the patient is severely hypoxic.
  • Methemoglobinemia: Causes SpO₂ to reliably plateau around 85%, regardless of actual arterial PaO₂.

Arterial Blood Gas (ABG)

  • When to draw an ABG: If the patient is critically ill, if SpO₂ drops unexpectedly, or if you suspect hypercapnia (rising CO₂) in a patient with COPD or tiring asthma.
  • Key Values: PaO₂ (oxygenation), PaCO₂ (ventilation), pH (acid-base status).

3. Targeted Oxygen Delivery

The historical approach of "giving high flow oxygen to everyone" is dangerous. Oxygen targets must be prescribed.

Group 1: Standard Target (SpO₂ 94% – 98%)

  • Profile: Acutely ill patients not at risk of Type II Respiratory Failure (COPD).
  • Examples: Asthma exacerbation, pneumonia, PE, acute HF, sepsis, trauma.

Group 2: COPD / Hypercapnia Risk Target (SpO₂ 88% – 92%)

  • Profile: Patients with known COPD, severe chest wall deformities, severe obesity-hypoventilation syndrome.
  • The Danger (Haldane Effect): Delivering too much oxygen displaces CO₂ from hemoglobin, increasing PaCO₂. It also alters pulmonary blood flow to poorly ventilated areas. This causes potentially fatal respiratory acidosis.
⚠️ Clinical Caveat (The STEMI/Trauma Exception): If a patient with COPD is having an acute STEMI or major trauma, do not withhold oxygen in the acute phase. Treat the saturation to prevent end-organ ischemia first; manage the resulting hypercapnia/pH with Non-Invasive Ventilation (BiPAP) if needed after stabilization.

4. Delivery Systems: The Clinician's Toolkit

A. Low-Flow Systems

These devices provide oxygen at a flow rate lower than the patient's inspiratory demand. The patient draws in room air, making the exact FiO₂ variable.

DeviceFlow RateApprox FiO₂Key Point
Nasal Cannula1 – 6 L/min24% – 44%Best for stable patients, mild hypoxia.
Simple Face Mask5 – 10 L/min35% – 50%Must be ≥5 L/min to flush exhaled CO₂.
Non-Rebreather Mask (NRBM)10 – 15 L/min60% – 90%One-way valve; reservoir bag must be inflated before placing on patient.

B. High-Flow / Fixed-Performance Systems

These devices meet or exceed patient flow demand, delivering precise FiO₂.

DeviceFlow / MechanismFiO₂ controlClinical role
Venturi MaskBernoulli principle, precise air entrainmentFixed (24%, 28%, 35%, etc.)Gold standard for COPD — prevents over-oxygenation.
High Flow Nasal Cannula (HFNC)Up to 60 L/min heated, humidified blended gas (FiO₂ 0.21 – 1.0)TitratableWashes out dead space, provides low-level PEEP, stents alveoli.

5. Pathology-Specific Oxygen Strategies

1. Chronic Obstructive Pulmonary Disease (COPD)

  • Mechanism: Chronic hyperinflation and V/Q mismatch. Risk of CO₂ retention.
  • Strategy: Target 88%–92%. Start with 24% or 28% Venturi mask. Monitor ABGs for respiratory acidosis. Escalate to BiPAP if pH drops with rising CO₂.

2. Acute Asthma Exacerbation

  • Mechanism: Reversible bronchospasm with mucus plugging. Initially hyperventilate (low CO₂).
  • Strategy: Do not restrict oxygen. Target 94%–98% while administering bronchodilators. A normal or high CO₂ in an asthma attack is a sign of impending respiratory arrest.

3. Pneumonia and ARDS (Consolidation/Shunt)

  • Mechanism: Alveoli filled with pus/fluid (Shunt physiology).
  • Strategy: Simple O₂ increases are less effective. They require positive pressure. Use HFNC early or CPAP to recruit alveoli.

4. Pulmonary Embolism (PE)

  • Mechanism: Dead Space Ventilation (ventilated without perfusion).
  • Strategy: Target 94%–98%. Start high (NRBM); hypoxemia may be refractory depending on clot burden.

5. Interstitial Lung Disease (ILD)

  • Mechanism: Thickened alveolar walls limiting diffusion.
  • Strategy: Rapid desaturation with exertion. HFNC may help during exacerbations. Note: For chronic, stable ILD on home oxygen, the resting saturation target is often lower (88–92%) to minimize oxygen toxicity from long-term exposure.

6. Risks and Complications of Oxygen

  • Oxygen Toxicity: Prolonged 100% O₂ produces free radicals causing direct alveolar damage.
  • Absorption Atelectasis: Washing out bodily nitrogen (alveolar stent) with pure oxygen causes alveoli to collapse when O₂ is absorbed.
  • Fire Hazard: Oxygen strongly supports combustion. Strict prohibition of smoking and static electricity near oxygen systems.

7. The Core Checklist

  • Prescribe It – Oxygen is a drug. Provide a target.
  • Verify the Setup – NRBM bag inflated; Simple Mask flow ≥5 L/min.
  • Check the Device/Site – Probe site clean, warm, free of nail polish/henna.
  • CXR Correlation – If SpO₂ 80% on 15L NRB, consider pneumothorax or kinked tubing.
  • Reassess – Always recheck patient 5–10 min after any change.
  • Wean proactively – Give only what is necessary to meet the target.

Updated clinical review — incorporates physiology, targeted ranges, and the STEMI/trauma exception.
Based on current BTS/ATS/ERS principles. Oxygen is a drug; prescribe it wisely.